BSX · Earnings call · 2026Q3T · Full report

Competition and Market Share

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 43 · Surprise 42

Management said new technologies and dynamically changing adoption of PFA form factors have eroded Boston Scientific’s formerly strong EP share position, with the cyber incident accelerating some of the shift. It expects further PFA share erosion until FARAWAVE Ultra launches, now expected in early 2028, and described 2027 as a challenging year for EP despite a healthy market. The company is focusing EP teams on areas where it believes it can compete effectively, including de novo atrial fibrillation procedures and its FARAWAVE, VersaCross, and WATCHMAN portfolio. Management also cited a new competitive launch in WATCHMAN’s market in 2027 and expects market conditions to remain pressured until improvement over time.

Key facts

• Boston Scientific expects continued erosion of its PFA share position until FARAWAVE Ultra launches, now expected in early 2028.
• Boston Scientific expects to continue ceding EP share in 2027 at rates similar to H2 2026 until an ICE launch in H2 2027 and a FARAPULSE Ultra upgrade, ideally in late Q4 2027 or early Q1 2028.